Controls severe or incapacitating allergic conditions. ANDA 216715, held by Amneal. Prednisolone Sodium Phosphate.
As of Nov 16, 2026, ANDA 216715 (Prednisolone Sodium Phosphate), held by Amneal, was first approved by FDA on Oct 25, 2022, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 25, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prednisolone Sodium PhosphateEQ 15MG BASE/5ML · solution;oral | Prednisolone Sodium Phosphate | Rx |
| Jul 23, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 25, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters